600535.SS
600535.SS
CNE000001C81
TASLY PHARMACEUTICAL GROUP CO L
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue 8.236.477.438 8.498.141.862
3.1%
Cost of Revenue 2.729.994.134 2.792.252.552
2.2%
Gross Profit 5.506.483.304 5.705.889.310
3.5%
4.052.009.183 4.211.413.215
3.8%
Operating Income 1.454.474.122 1.494.476.095
2.7%
Pretax Income 1.345.215.746 1.068.689.803
25.9%
Net Income Common Stockholders 1.104.961.926 955.586.169
15.6%
-- --
--
-- --
--
ende